OBJECTIVE: To determine the necessity for monitoring of anti-factor Xa levels in pregnant women taking low molecular weight heparin (LMWH). STUDY DESIGN: A review of a hematological database with chart review was undertaken to identify patients on LMWH. Levels were drawn monthly. They were considered suboptimal if prophylactic and therapeutic doses of LMWH had an anti-Xa value <0.2 U/mL and 0.6 U/mL, respectively. Variables of interest included age, parity, thrombophilias, and antiphospholipid antibody syndrome. RESULTS: Of 30 patients, three required therapeutic-dose LMWH and 27 were on prophylaxis. Sixty-six percent on a therapeutic dose required a dose change, whereas 11% on a prophylactic dose were changed (p = 0.013). None of the variables were predictive of a need for change. One thromboembolic event was noted while on prophylactic-dose LMWH. CONCLUSIONS: No single variable is predictive of a need for dose change. Patients on a therapeutic dose were more likely to need change.
OBJECTIVE: To determine the necessity for monitoring of anti-factor Xa levels in pregnant women taking low molecular weight heparin (LMWH). STUDY DESIGN: A review of a hematological database with chart review was undertaken to identify patients on LMWH. Levels were drawn monthly. They were considered suboptimal if prophylactic and therapeutic doses of LMWH had an anti-Xa value <0.2 U/mL and 0.6 U/mL, respectively. Variables of interest included age, parity, thrombophilias, and antiphospholipid antibody syndrome. RESULTS: Of 30 patients, three required therapeutic-dose LMWH and 27 were on prophylaxis. Sixty-six percent on a therapeutic dose required a dose change, whereas 11% on a prophylactic dose were changed (p = 0.013). None of the variables were predictive of a need for change. One thromboembolic event was noted while on prophylactic-dose LMWH. CONCLUSIONS: No single variable is predictive of a need for dose change. Patients on a therapeutic dose were more likely to need change.
Authors: Nancy L Shapiro; Michelle A Kominiarek; Edith A Nutescu; Aimee B Chevalier; Judith U Hibbard Journal: Pharmacotherapy Date: 2011-07 Impact factor: 4.705
Authors: Lucia Stanciakova; Miroslava Dobrotova; Pavol Holly; Jana Zolkova; Lubica Vadelova; Ingrid Skornova; Jela Ivankova; Matej Samos; Tomas Bolek; Marian Grendar; Jan Danko; Peter Kubisz; Jan Stasko Journal: Clin Appl Thromb Hemost Date: 2022 Jan-Dec Impact factor: 2.389
Authors: Jesus Vera-Aguilera; Hindi Yousef; Diego Beltran-Melgarejo; Teng Hugh Teng; Ramos Jan; Mary Mok; Carlos Vera-Aguilera; Eduardo Moreno-Aguilera Journal: Adv Hematol Date: 2016-05-12